Dr Sathish Harinarayanan

Professional statement

Dr Sathish Harinarayanan is a distinguished consultant clinical oncologist based in the south coast of England providing expertise services for patients with bowel cancers, head & neck cancers, non-melanomatous skin cancers arising in the head & neck area, and complex thyroid cancers requiring radiotherapy.

His areas of expertise also include the MRL-SABR treatment for oligometastatic cancer, a complex and modern radiotherapy technique which delivers high-dose radiotherapy more precisely to cancer with limited spread to other parts of the body - which is otherwise not possible with conventional CT guided radiotherapy machines. Dr Harinarayanan is also accredited to provide Proton radiotherapy treatments.

Dr Harinarayanan is dedicated to providing the highest standard of care in clinical oncology. After graduating with a medical degree and doing various medical rotations across renowned London and West Midlands hospitals, he undertook higher specialist oncology training around Wessex hospitals and London Hospitals before taking up his consultant post at University Hospital of Southampton.

With a demonstrated commitment to excellence, he undertook and completed a prestigious proton therapy clinical education programme at the University of Pennsylvania and the MRL-SABR accreditation from GCUK and PGC, from the Institute of Cancer Research, London.

Beyond clinical practice, Dr Harinarayanan holds membership with the British Association of Head & Neck Oncology, served as co-chair of the Wessex Head and Neck Cancer alliance group, is member of the panel for the Wessex clinical oncology trainees, and is the elected governor for medical and dental staffing for Southampton attending the trust board meetings with executive and non-executive members of the trust.

Dr Harinarayanan actively participates in research, being the principal investigator for the country’s leading trials like PATHOS, APHRODITE for organ preserving strategies with radiotherapy for rectal cancer patients who wish to avoid permanent stoma bags. He has also acted at a co-investigator capacity for other leading UK clinical trials in Wessex like CHECKMATE 642, LiTEFORM, KEYNOTE 412, INNOVATE and ToRPEDO and recruited several patients so far.